Seaward Management Limited Partnership trimmed its stake in Pfizer, Inc. (NYSE:PFE) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,150,884 shares of the biopharmaceutical company’s stock after selling 21,689 shares during the period. Pfizer makes up approximately 1.9% of Seaward Management Limited Partnership’s portfolio, making the stock its 13th biggest holding. Seaward Management Limited Partnership owned approximately 0.07% of Pfizer worth $38,658,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of PFE. D. Scott Neal Inc. grew its position in Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer during the first quarter valued at approximately $121,000. Cascade Investment Advisors Inc. grew its position in Pfizer by 89.1% during the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 2,200 shares during the last quarter. Perennial Advisors LLC grew its position in Pfizer by 7.9% during the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 376 shares during the last quarter. Finally, Patten Group Inc. grew its position in Pfizer by 5.1% during the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 252 shares during the last quarter. Institutional investors own 69.36% of the company’s stock.
In related news, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the transaction, the insider now directly owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 374,621 shares of company stock valued at $12,796,098. Corporate insiders own 0.06% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) opened at $35.38 on Wednesday. Pfizer, Inc. has a twelve month low of $30.51 and a twelve month high of $36.78. The company has a market capitalization of $210,412.95, a PE ratio of 14.12, a P/E/G ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same period last year, the company earned $0.61 EPS. Pfizer’s revenue for the quarter was up .9% on a year-over-year basis. analysts predict that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. Pfizer’s dividend payout ratio is currently 79.01%.
A number of analysts have recently weighed in on PFE shares. Berenberg Bank reissued a “hold” rating and set a $36.00 price objective (down previously from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. BMO Capital Markets reissued a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research note on Friday, November 10th. UBS AG reissued a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research note on Monday, July 31st. Finally, Cowen and Company set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average price target of $38.48.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.